StockData
Scinai Immunotherapeutics Ltd. logo

Scinai Immunotherapeutics Ltd. (SCNI) stock

SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 6/30
$0.37−0.01 (-1.40%)

Close on Nov 18, 2026Market cap $1.27MP/E –Yield –

Scinai Immunotherapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Scinai Immunotherapeutics's R&D Expenses for the twelve months ending Dec 31, 2021 was $3.25M. For fiscal 2025 it was $2.37M, down 57.2% from the year before. The highest annual figure on record is $16.01M in fiscal 2020.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.37M-57.2%
FY2024Dec 31, 2024$5.53M+6.2%
FY2023Dec 31, 2023$5.21M-9.6%
FY2022Dec 31, 2022$5.77M+77.4%
FY2021Dec 31, 2021$3.25M-79.7%
FY2020Dec 31, 2020$16.01M+195.6%
FY2017Dec 31, 2017$5.42M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2023Jun 30, 2023$1.45M+23.1%
Q1 FY2023Mar 31, 2023$2.00M–
Q2 FY2022Jun 30, 2022$1.97M–
Q1 FY2022Mar 31, 2022$1.16M–
Q4 FY2021Dec 31, 2021$1.18M–

More Scinai Immunotherapeutics figures

See a number that looks wrong?